Hims & Hers Health, Inc. Class A Common Stock (HIMS)

As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from a controversial provider of compounded GLP-1 medications to a cornerstone of the global pharmaceutical distribution network. The catalyst for this transformation was [...]

On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth.

Not many things have gone right for Novo Nordisk recently, but this is one of them.

As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers Health (NYSE: HIMS), a company that has navigated a volatile journey from a telehealth disruptor to a central pillar of the modern [...]

HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims & Hers Health Inc (NYSE: HIMS) higher.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant Novo Nordisk (NYSE: NVO). The deal, which effectively ends a high-stakes patent dispute, has propelled HIMS shares to record highs, closing the

Brokerages have turned bullish on HIMS since its deal with Novo Nordisk earlier this week, with Barclays raising the stock’s price target to $29.

Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.

Hims & Hers Health has gotten torched over the last six months - since September 2025, its stock price has dropped 55.2% to $23.21 per share. This may have i...

Hims & Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.

As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a "wellness-lite" platform for hair loss and erectile dysfunction, Hims & Hers has evolved into a diversified healthcare titan. Today, the company finds itself [...]

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners.

On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.

The financial landscape on March 9, 2026, has reached a critical tipping point, marking one of the most aggressive sector rotations in modern market history. As technology-heavy indices struggle to find their footing under the weight of "AI fatigue" and new trade pressures, investors have staged a massive exodus into

Hims & Hers stock traded more than 40% higher after the deal was announced.

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 41.7% in the morning session after the company announced a collaboration wi...